Population-Based vs Health System and Insurer Records: Significant Underdiagnosis of Polycystic Ovary Syndrome (PCOS)
Authors' conclusion
Our data revealed a substantially lower rate of PCOS in HSIR relative to population-based studies in the United States, the United Kingdom, and South Korea, likely indicating that PCOS is underdiagnosed and/or underreported. Overall, these findings highlight the critical need to improve the awareness of health care practitioners and payers, and likely the public at large, regarding PCOS.
Study context
- Population
- Studies reporting PCOS prevalence in the general population and in HSIR, from the same populations in 3 countries (United States, UK, South Korea); PubMed and Embase through July 20237 population-based, 11 HSIR-based studies
- Participants
- 7 vs 11
- Comparison
- PCOS prevalence in population-based studies vs Health System or Insurer Records (HSIR)
- Population-basedn = 7reference
- HSIRn = 11
- Outcome
- Extent of PCOS underdiagnosis: PCOS prevalence in population-based vs HSIR-based studies
Methodological details6583 records identified
- 6583 records identified
Pooled result
As reported in the abstract
PCOS prevalence
- United States, population-based studies
- between 4% and 19.6%
- United States, HSIR-based studies
- 0.2% to 5.2%
- UK, HSIR-based study
- 1.34%
- UK, population
- around 8%
- South Korea, 2 population-based studies
- 4.9% and 7%
- South Korea, one HSIR
- 0.12% to 0.33%
- South Korea, another HSIR
- 4.3%
Further pooled results
- Where data were available, PCOS detection in HSIR appeared to improve over time, though still far from the actual population prevalence
Original publication
Population-Based vs Health System and Insurer Records: Significant Underdiagnosis of PCOS. J Clin Endocrinol Metab. Published 21 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →